RxDoctor Payments Data

Jodeanna Sweeney

Family · Central Point, ORNPI 1487828190

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $32,561 of the $45,407 with a category attached, or 71.7%. Novo Nordisk accounts for 98.7% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2022 at $17,046 and has fallen 87.1% since, to $2,202 in 2025. Among family clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$45,407in general payments, 2019–2025

Across 108 payments — averaging $420.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$45K
  • Lilly USA, LLC$322
  • Medtronic$82
  • Madrigal Pharmaceuticals$65
  • Johnson & Johnson$63
  • Rhythm Pharmaceuticals, Inc.$40

What the payments were for

  • Speaking & faculty fees$32,56172%
  • Travel & lodging$8,75319%
  • Food & beverage$3,9329%
  • Education$1610%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$45,407 in reported general payments places this provider in the 95th percentile of 1,130 family providers in Oregon.

See all family providers in Oregon

Medicare billing

Part B allowed, 2024
$8,293
Medicare patients
41
Services billed
94

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide28$28,945
OzempicSemaglutide25$24,409
Topiramate47$353
Omeprazole29$211
Zonisamide15$192
Bupropion XlBupropion Hcl11$40

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$322$28,94528 claims
Novo NordiskOzempic$44,834$24,40925 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,130 family providers in Oregon.

Other family in Central Point

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →